Physician profile
Daming Zhu
NPI 1881742336
$3,614.16
in general payments reported to CMS, 2019-2025
27 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $172 · 2021: $244 · 2022: $732 · 2023: $838 · 2024: $449 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $430.12 | 2019-2025 | Mitraclip, Assurity, Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $326.16 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $317.67 | 2019-2022 | |
| Amgen INC. | $301.42 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $260.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.12 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $252.94 | 2019-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $208.65 | 2019-2024 | |
| Abiomed | $179.42 | 2022-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $176.24 | 2019-2024 | |
| Pfizer INC. | $126.93 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $109.48 | 2019-2023 | Farxiga |
| Mylan Specialty L.P. | $105.70 | 2019-2023 | Yupelri |
| United Therapeutics Corporation | $96.47 | 2020-2024 | Tyvaso |
| Edwards Lifesciences Corporation | $92.31 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $74.39 | 2022 | |
| Inspire Medical Systems, INC. | $45.30 | 2023 | Inspire |
| Kestra Medical Technology Services, INC. | $40.05 | 2025 | Assure Wcd |
| Shire North American Group INC | $38.41 | 2019 | |
| Scpharmaceuticals INC. | $35.22 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $27.99 | 2023 | Opsumit |
| Novo Nordisk INC | $22.77 | 2024 | Wegovy |
| Amarin Pharma, INC. | $20.22 | 2022 | |
| Lundbeck LLC | $19.93 | 2019 | |
| Baxter Healthcare | $19.50 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $19.44 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daming Zhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.